VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 26, 2012) - Eternity Healthcare Inc. (OTCBB:ETAH) (the "Company"), a medical technology company, is pleased to announce today that has filed in Canada for regulatory approval of its needle-free injection device. The Company introduces a new device for the injection of medicine into the body that does not require a needle. The technology has proven to be effective in administering greater than 95% of the medicine into the skin without the use of a needle. The technology is extremely fast and pain-free. This technology is believed to be ideal for diabetes patients for the injection of insulin. According to American Diabetes Association there are 25.8 million diabetes in the United States. Current treatment is the use of Insulin for a vast number of these patients. Insulin must be injected daily, a cumbersome and unpleasant practice. The needle-free injection device should make insulin therapy convenient and patient friendly. The estimated sale of such device could be in the several hundred millions of dollars.

Prior to commercialization of the device, the Company should obtain regulatory approvals in the countries which is planned to be marketed, including United States and Canada. The regulatory process for the device could take 3-5 months.

About Eternity Healthcare

Eternity Healthcare is a publically listed company in the United States under the stock symbol of "ETAH". The Company is the leader in medical technologies with state of the art medical devices, including diagnostic kits, digital cholesterol readers, injection-free needles and many more. For further information visit the Company's website: [ www.eternityhealthcare.com ].

Notice Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.